FORM 3

44 MONTGOMERY STREET

40TH FL

(Street)

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## OMB APPROVAL OMB Number: 32350104

Estimated average burden hours per response: 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

		F				6(a) of the Securities Exchar he Investment Company Act		1934				
Name and Address of Reporting Person*     BVF PARTNERS L P/IL			2. Date of Event Requiring Statement (Month/Day/Year) 12/18/2020		ement	3. Issuer Name and Ticker or Trading Symbol <u>CytomX Therapeutics, Inc.</u> [ CTMX ]						
(Last) (First) (Middle) 44 MONTGOMERY STREET						Relationship of Reporting Issuer (Check all applicable)		,,		5. If Amendment, Date of Original Filed (Month/Day/Year)		
40TH FL (Street)						Director  Officer (give title below)	_	(specify		eck Applicable	int/Group Filing e Line) by One Reporting	
SAN FRANCISCO C	A 94104								X	Form filed	by More than One Person	
(City) (Sta	te) (Zip)											
		Ta	ble I - Non	-De	erivati	ve Securities Benefic	cially O	wned				
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)	3. Own Form: (D) or I (I) (Inst	Direct ndirect	4. Nature of Indirect Beneficial Ownership (Instr. 5)				
Common Stock, \$0.00001 par value per share <sup>(1)</sup>					2,945,743		(2)					
Common Stock, \$0.00001 par value per share <sup>(1)</sup>					2,164,406	Г	(3)					
Common Stock, \$0.00001 par value per share <sup>(1)</sup>					358,450	Г	(4)					
	(					Securities Beneficia			)			
1. Title of Derivative Security (Instr. 4)  2. Date Exercisal Expiration Date (Month/Day/Year			n Date		Underlying Derivative Security (Instr. 4) Co		Convei or Exei	cise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr.		
		Date Exercisable	Expiration Date		Title	Amount or Number of Shares	Price o Derivat Securit	ive	Direct (D) or Indirect (I) (Instr. 5)	5)		
1. Name and Addres	ss of Reporting Perso	on*										
(Last) 44 MONTGOM 40TH FL	(First) ERY STREET	(Mide	dle)									
(Street) SAN FRANCISCO	CA	9410	04									
(City)	(State)	(Zip)										
1. Name and Address of Reporting Person* <u>BIOTECHNOLOGY VALUE FUND L P</u>												
(Last)	(First)	(Mide	dle)	_								

(City)	(State)	(Zip)
1. Name and Addro		Person*
BVF I GP L		
(Last)	(First)	(Middle)
44 MONTGON	MERY ST., 407	TH FLOOR
(Street)		
SAN FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Addre		
		ALUE FUND II
(Last)	(First)	(Middle)
44 MONTGON	MERY STREE	Γ
40TH FL		
(Street)		
FRANCISCO	CA	94104
(City)	(State)	(Zip)
1. Name and Addr	ess of Reporting	Person <sup>*</sup>
BVF II GP I	<u>LC</u>	
-		(Middle)
(Last)	(First)	(wildule)
(Last) 44 MONTGON	, ,	, ,
•	, ,	, ,
44 MONTGON  (Street) SAN	, ,	, ,
44 MONTGON (Street)	MERY ST., 407	TH FLOOR
(Street) SAN FRANCISCO (City)	CA (State)	94104 (Zip)
(Street) SAN FRANCISCO (City)  1. Name and Addre	CA  (State)  ess of Reporting	94104 (Zip)
(Street) SAN FRANCISCO (City)  1. Name and Address Biotechnology	CA  (State) ess of Reporting	94104 (Zip) Person* ading Fund OS LP
(Street) SAN FRANCISCO (City)  1. Name and Addre	CA  (State) ess of Reporting gy Value Tr  (First)	94104  (Zip)  Person* ading Fund OS LP  (Middle)
(Street) SAN FRANCISCO (City)  1. Name and Addred Biotechnology (Last) P.O. BOX 309	CA  (State) ess of Reporting gy Value Tr  (First)	94104  (Zip)  Person* ading Fund OS LP  (Middle)
(Street) SAN FRANCISCO (City)  1. Name and Addre Biotechnolog (Last)	CA  (State) ess of Reporting gy Value Tr  (First) UGLAND HO	94104  (Zip)  Person* ading Fund OS LP  (Middle)  USE
(Street) SAN FRANCISCO (City)  1. Name and Addre Biotechnolog (Last) P.O. BOX 309	CA  (State) ess of Reporting gy Value Tr  (First)	94104  (Zip)  Person* ading Fund OS LP  (Middle)
(Street) SAN FRANCISCO (City)  1. Name and Addre Biotechnolog (Last) P.O. BOX 309 (Street) GRAND	CA  (State) ess of Reporting gy Value Tr  (First) UGLAND HO	94104  (Zip)  Person* ading Fund OS LP  (Middle)  USE
(Street) SAN FRANCISCO (City)  1. Name and Addre Biotechnolog (Last) P.O. BOX 309 (Street) GRAND CAYMAN (City)  1. Name and Addre	CA  (State) ess of Reporting gy Value Tr  (First) UGLAND HO  E9  (State) ess of Reporting	94104  (Zip)  Person* ading Fund OS LP  (Middle)  USE  KY1-1104  (Zip)
(Street) SAN FRANCISCO (City)  1. Name and Addred Biotechnology (Last) P.O. BOX 309 (Street) GRAND CAYMAN (City)	CA  (State) ess of Reporting gy Value Tr  (First) UGLAND HO  E9  (State) ess of Reporting	94104  (Zip)  Person* ading Fund OS LP  (Middle)  USE  KY1-1104  (Zip)
(Street) SAN FRANCISCO (City)  1. Name and Addre Biotechnolog (Last) P.O. BOX 309 (Street) GRAND CAYMAN (City)  1. Name and Addre	CA  (State) ess of Reporting gy Value Tr  (First) UGLAND HO  E9  (State) ess of Reporting	94104  (Zip)  Person* ading Fund OS LP  (Middle)  USE  KY1-1104  (Zip)

GRAND CAYMAN	E9	KY1-1104					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person*  BVF GP HOLDINGS LLC							
(Last) 44 MONTGOM	(First) IERY ST., 40TH F	(Middle) FLOOR					
(Street) SAN FRANCISCO	CA	94104					
(City)	(State)	(Zip)					
Name and Address of Reporting Person*     BVF INC/IL							
(Last) 44 MONTGOM 40TH FL	(First) IERY STREET	(Middle)					
(Street) SAN FRANCISCO	CA	94104					
(City)	(State)	(Zip)					
1. Name and Address of Reporting Person*  LAMPERT MARK N							
(Last) (First) (Middle) 44 MONTGOMERY STREET 40TH FL							
(Street) SAN FRANCISCO	CA	94104					
(City)	(State)	(Zip)					

## **Explanation of Responses:**

- 1. This Form 3 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- 2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
- 3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
- 4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.

BVF Partners L.P., By:
BVF Inc., its general
partner, By: /s/ Mark N.
Lampert, President
Biotechnology Value
Fund, L.P., By: BVF
Partners L.P., its
investment manager, By:
BVF Inc., its general

partner, By: /s/ Mark N.

Lampert, President

BVF I GP LLC, By: BVF

**GP HOLDINGS LLC, its** 

sole member, By: /s/ Mark 12/28/2020

N. Lampert, Chief

**Executive Officer** 

Biotechnology Value Fund

II, L.P., By: BVF Partners

L.P., its investment

manager, By: BVF Inc., its 12/28/2020

general partner, By: /s/

Mark N. Lampert,

**President** 

BVF II GP LLC, By: BVF

GP HOLDINGS LLC, its

sole member, By: /s/ Mark 12/28/2020

N. Lampert, Chief

**Executive Officer** 

BVF Partners OS Ltd., By:

BVF Partners L.P., its sole

member, By: BVF Inc., its 12/28/2020

general partner, By: /s/

Mark N. Lampert,

**President** 

Biotechnology Value

Trading Fund OS LP, By:

BVF Partners L.P., its

investment manager, BVF 12/28/2020

Inc., its general partner,

By: /s/ Mark N. Lampert,

**President** 

BVF GP Holdings LLC,

By: /s/ Mark N. Lampert, 12/28/2020

**Chief Executive Officer** 

BVF Inc., By: /s/ Mark N.

Lampert, President

<u>12/28/2020</u> 12/28/2020

/s/ Mark N. Lampert

\*\* Signature of Reporting

.

⊃ers∩n

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.